Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)
2014 · Annals of Oncology · 137 citations
https://doi.org/10.1093/annonc/mdu455
W
W. Weikel
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
108
Papers
1.7K
Citations
23
h-index
32
i10-index
W. Weikel is an academic researcher from Johannes Gutenberg University Mainz. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Breast Cancer Treatment Studies & Endometrial and Cervical Cancer Treatments. The author has an h-index of 23, co-authored 92 publications.
Papers by this author
worksp53 expression and resistance against paclitaxel in patients with metastatic breast cancer
2003 · Journal of Cancer Research and Clinical Oncology · 45 citations
https://doi.org/10.1007/s00432-003-0430-1
Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing
2005 · Breast Cancer Research · 34 citations
https://doi.org/10.1186/bcr991
Immunhistochemischer Nachweis und prognostische Bedeutung von p 53 im Primärtumor von Mammakarzinompatientinnen
1995 · Geburtshilfe und Frauenheilkunde · 3 citations
https://doi.org/10.1055/s-2007-1023313
[Histology of chorioamnionitis: relations to maternal and fetal infection parameters].
1993 · PubMed · 3 citations
Effect of histological grade, steroid hormone receptor status, HER2 SCO, HER2 AMP and HER2 COM on overall survival
2011 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.34777.v1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat